Taysha Gene Therapies, Inc. has priced an underwritten public offering of 32,500,001 shares of its common stock at a price to the public of $6.00 per share. The company also offered pre-funded warrants to purchase 833,333 shares of its common stock at an offering price of $5.999 per pre-funded warrant. The gross proceeds from the offering are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about June 26, 2026, subject to customary closing conditions.

All securities are being offered by Taysha, which has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. A shelf registration statement was filed with the Securities and Exchange Commission (SEC) on November 4, 2025, and became automatically effective upon filing. The offering is being made only by means of a written prospectus and prospectus supplement.

Jefferies, Goldman Sachs & Co. LLC, Piper Sandler, and Cantor are acting as joint book-running managers for the proposed offering. Baird is serving as the lead manager. Taysha is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system.

Taysha’s lead clinical program, TSHA-102, is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies. The company leverages its manufacturing process and a clinically and commercially proven AAV9 capsid to translate treatments from bench to bedside.

B of A Securities analyst Tazeen Ahmad has maintained a Buy rating on Taysha Gene Therapies. The firm raised the price target to $10 from $9.

Rating and Target Details

The revised price target reflects an increased valuation outlook for the company. The previous target was $9.